Sernova

Sernova Opens the Market Thursday, June 2, 2022

Sernova Wild Caipi

Sernova Red Citrus

Innovating Cell-Based Solutions for Type 1 Diabetes ft. Jonathan Rigby, CEO, Sernova

Sernova FDA Clearance: Cell Pouch for Hypothyroidism Treatment

Whiteboard: Sernova's Cell Pouch™ for Type 1 Diabetes (T1D)

Sernova Aktie Analyse | Sernova Corporation: Sernova Aktie als große Chance für die Zukunft!

Sernova Corp. (TSXV: SVA) - 2022 TSX Venture 50

Sernova Commercial

Sernova’s Cell Pouch System - An Update on the Path to Insulin Independence

Sernova's BREAKTHROUGH Cell Pouch Fights Type-1 Diabetes!

T1D Cure Research: Sernova Shares Update on Six Participants

Sernova Clinical Trial News: Big Update Coming Soon!

Sernova Global Partnership Family Office Presentation

Sernova

Sernova KOL Event on Thyroid Disease and Potential for Cell Therapy as a Novel Treatment Approach

Sernova Cell Pouch: 5-Year Study Results for Type-1 Diabetics [2024 Update]

Sernova

Sernova (TSXV: SVA) “CGM” will be provided to patients for a clinical trial of its Cell Pouch™.

Viví tu mejor verano con Sernova

Epsiode 50 Jonathan Rigby, Chairman and CEO, Sernova

Sernova

Great T1D Cell Pouch Results From Sernova for Islet Cell Transplantation

Sernova